ACROBiosystems AD
 
 

BRIC

검색 닫기

전체 메뉴

팝업 닫기

바이오젬스코리아

  • 등록2026.07.09
  • 조회11
Anti-Human CD3 SAFIRE Purified ( OKT3 ) [ 05121-25 ] : SAFIRE AB

Anti-Human CD3 SAFIRE Purified ( OKT3 ) [ 05121-25 ] : SAFIRE AB

본 정보는 "바이오젬스코리아"(으)로 문의 바랍니다.



Anti-Human CD3 SAFIRE Purified ( Clone : OKT3 )  

SAFIRE(Sodium Azide Free Immensely Reduced Endotoxin) 제품은 면역세포 activation, blocking, neutralization 연구에 사용할 수 있는 BioGems의 기능성 항체 라인입니다. 이 제품은 career 및 sodium azide 를  전혀 포함하지 않으며,  in vivo 및 in vitro 사용가능한 0.01 EU/ug 이하의 내독소 수준으로 제조된 제품입니다.

OKT3 단일 클론 항체는 CD3/T 림프구 항원 수용체 복합체의 ε 사슬과 특이적으로 반응합니다.

CD3 복합체는 γ, δ 및 ε 사슬을 포함하며 모든 성숙한 T 림프구와 흉선 세포 계통에 의해 발현되는 TCR 복합체의 일부입니다.

CD3는 신호 전달을 통해 항원 인식을 향상시키며, OKT3 항체는 면역 억제제로 간, 심장 및 신장 동종이식 거부반응에 효과적인 치료제로 입증되었습니다.

Catalog Number : 05121-25  ;  Clone : OKT3 
SIZE가격 (부가세별도)제품번호
100 μg
$160.00 
05121-25 -100
500 μg
$295.00 
05121-25 -500

 

ADDITIONAL OKT3 FORMATS 

CAT.NO.FORMATSTARTING FROM
05121-20Purified$ 115.00
05121-25SAFIRE Purified$ 160.00
05121-40BG Violet 450$ 95.00
05121-60PE$ 50.00
05121-80APC$ 65.00
05121-50FITC$ 40.00
05121-70PerCP-Cyanine5.5$ 135.00
05121-77PE-Cyanine7$ 95.00

 

[ 제품 인용 최신 논문 ] 

  1. Su Z, Chen Z, Lin J, Yu W, Zeng Y, Zhang W, Li Q, Lin Y, Liu Z, Zheng G, Li L, Xie Z. Neutrophil membrane-coated and MMP2-responsive nanoparticles deliver PIM1 inhibitor to alleviate inflammatory arthritis through inhibiting Th17 cell differentiation. J Nanobiotechnology. 2026 Mar 14;24(1):379. doi: 10.1186/s12951-026-04280-x. PMID: 41827025; PMCID: PMC13101309.
  2. Cheng C, Su H, Li X, Li R, Yang Q, Guan T, Li M, Ou C. MiR-1290 in natural killer cell derived extracellular vesicles: a pathogenic mediator of lupus nephritis and therapeutic target for th17 regulation. J Nanobiotechnology. 2026 Mar 2;24(1):203. doi: 10.1186/s12951-026-04212-9. PMID: 41772611; PMCID: PMC12955233.
  3. Su Z, Zeng Y, Li Q, Li J, Zheng G, Zhang W, Xiao Z, Chen Z, Lin Y, Liu Z, Wu Y, Lin J, Yu W, Xie Z. Pim1 Serves as a Therapeutic Target for Inflammatory Arthritis via Mitochondrial Metabolism and Th17 Cell Differentiation. Research (Wash D C). 2026 Feb 27;9:1137. doi: 10.34133/research.1137. PMID: 41767599; PMCID: PMC12946387.
  4. Li XY, Xie XQ, Wei BC, Sun XZ, Chen MX, Liu RF, Tao QX, Huang YH, Wang Q, Ma SS, Wei L, Xiao R, Liu ZY, Yu JM, Wu M, Chen D. IL-21 enhances the cytotoxicity of intratumoral CD8+ T cells, improving radiation efficacy. JCI Insight. 2026 Jan 8;11(4):e190531. doi: 10.1172/jci.insight.190531. PMID: 41505202; PMCID: PMC12956009.
  5. Liu X, Liu Q, Guo D, Zhao Z, Wang J, Xiang Y, Wang K, Yang L, Zhu K, Wang L, Li R, Gao X, Zhang C, Cheng Y, Yan D, Tong Y. Hyperglycemia drives lmmune evasion in colorectal cancer through VISTA stabilization. Cell Commun Signal. 2026 Jan 7;24(1):88. doi: 10.1186/s12964-025-02642-w. PMID: 41501851; PMCID: PMC12870058.
  6. Shi W, Luo Y, Wang Y, Burrows JM, Black D, Civitarese A, Perlaza-Jimenez L, Zhang P, Manning M, Tuano N, Rentería ME, Xiao C, Tey SK, Rosenbluh J, Smith C, Chenevix-Trench G, Beesley J. CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer. NPJ Breast Cancer. 2026 Jan 21;12(1):24. doi: 10.1038/s41523-025-00888-8. PMID: 41565695; PMCID: PMC12891518.
  7. Tong Y, Liu Q, Zhao Z, Wang K, Wang J, Han B, Zhu K, Yang L, Zhang C, Guo D, Yan D, Liu X. UBE2C-PI3K/AKT-mediated upregulation of MTHFD2 promotes tumor progression in hepatocellular carcinoma. Int Immunopharmacol. 2026 Feb 1;170:116081. doi: 10.1016/j.intimp.2025.116081. Epub 2025 Dec 27. PMID: 41456492.
  8. Lin Q, Wu F, Zhang L, Zhang Y, Sun S, Wu X, Yu H. EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation. Acta Biochim Biophys Sin (Shanghai). 2026 Mar 3. doi: 10.3724/abbs.2026013. Epub ahead of print. PMID: 41772962.
  9. Zhang XY, Shi JB, Jin SF, Wang RJ, Li MY, Zhang ZY, Yang X, Ma HL. Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape. Cancer Commun (Lond). 2024 Jun;44(6):670-694. doi: 10.1002/cac2.12545. Epub 2024 May 12. PMID: 38734931; PMCID: PMC11194450.
  10. Yu W, Wang K, He Y, Shang Y, Hu X, Deng X, Zhao L, Ma X, Mu X, Li R, Gao Z. The potential role of lung microbiota and lauroylcarnitine in T-cell activation associated with checkpoint inhibitor pneumonitis. EBioMedicine. 2024 Aug 3:106:105267. doi: 10.1016/j.ebiom.2024.105267. Epub ahead of print. PMID: 39098109.
  11. Zhang X, Chen R, Huo Z, Li W, Jiang M, Su G, Liu Y, Cai Y, Huang W, Xiong Y, Wang S. Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer. Cancer Cell Int. 2024 Jun 29;24(1):225. doi: 10.1186/s12935-024-03412-3. PMID: 38951894; PMCID: PMC11218110.
  12. Liu L, Xiang Y, Shao L, Yuan C, Song X, Sun M, Liu Y, Zhang X, Du S, Hou M, Peng J, Shi Y. E3 ubiquitin ligase casitas B-lineage lymphoma-b modulates T-cell anergic resistance via phosphoinositide 3-kinase signaling in patients with immune thrombocytopenia. J Thromb Haemost. 2024 Apr;22(4):1202-1214. doi: 10.1016/j.jtha.2023.12.032. Epub 2024 Jan 4. PMID: 38184203.
  13. Zhang XY, Shi JB, Jin SF, Wang RJ, Li MY, Zhang ZY, Yang X, Ma HL. Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape. Cancer Commun (Lond). 2024 May 12. doi: 10.1002/cac2.12545. Epub ahead of print. PMID: 38734931.
  14. Qian Y, Sun Y, Shi P, Zhou X, Zhang Q, Dong Q, Jin S, Qiu L, Niu X, Zhou X, Zhao W, Wu Y, Zhai W, Gao Y. Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy. Acta Pharm Sin B. 2024 Mar;14(3):1150-1165. doi: 10.1016/j.apsb.2023.12.011. Epub 2023 Dec 19. PMID: 38486998; PMCID: PMC10935467.
  15. Su Z, Li J, Lin J, Li Z, Che Y, Zhang Z, Zheng G, Ye G, Yu W, Zeng Y, Xu P, Xu X, Xie Z, Wu Y, Shen H. TNF-α-Induced KAT2A Impedes BMMSC Quiescence by Mediating Succinylation of the Mitophagy-Related Protein VCP. Adv Sci (Weinh). 2024 Mar;11(10):e2303388. doi: 10.1002/advs.202303388. Epub 2023 Dec 25. PMID: 38145956; PMCID: PMC10933659.  [ BioGems 제품이나 Peprotech 으로 표기 ]
  16. Jin S, Wang H, Li Y, Yang J, Li B, Shi P, Zhang X, Zhou X, Zhou X, Niu X, Wu M, Wu Y, Zhai W, Qi Y, Gao Y, Zhao W. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy. Cell Commun Signal. 2024 Mar 11;22(1):173. doi: 10.1186/s12964-024-01555-4. PMID: 38462636; PMCID: PMC10926604.
  17. Han K, Li SS, Pan W, Xu MN, Zhong MZ, Zhang WJ, Huang XW, Zeng K. ERK/MEK Pathway Regulates Th17 Cell Differentiation in Patients with Pemphigus Vulgaris. Indian J Dermatol. 2023 Nov-Dec;68(6):724. doi: 10.4103/ijd.ijd_924_22. Epub 2024 Jan 9. PMID: 38371571; PMCID: PMC10868988.
  18. Zhang Z, Ji W, Huang J, Zhang Y, Zhou Y, Zhang J, Dong Y, Yuan T, Yang Q, Ding X, Tang L, Li H, Yin J, Wang Y, Ji T, Fei J, Zhang B, Chen P, Hu H. Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients. Clin Transl Med. 2022 Nov;12(11):e1072. doi: 10.1002/ctm2.1072. PMID: 36305631; PMCID: PMC9615475.
  19. Peng S, Chen S, Hu W, Mei J, Zeng X, Su T, Wang W, Chen Z, Xiao H, Zhou Q, Li B, Xie Y, Hu H, He M, Han Y, Tang L, Ma Y, Li X, Zhou X, Dai Z, Liu Z, Tan J, Xu L, Li S, Shen S, Li D, Lai J, Peng B, Peng Z, Kuang M. Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma. Cancer Immunol Res. 2022 Jun 3;10(6):728-744. doi: 10.1158/2326-6066.CIR-21-0931. PMID: 35476700.
  20. Pohida K, Lake CM, Yee D, Snow AL. Restimulation-Induced Cell Death (RICD): Methods for Modeling, Investigating, and Quantifying RICD Sensitivity in Primary Human T Cells via Flow Cytometric Analysis. Bio Protoc. 2022 Feb 20;12(4):e4326. doi: 10.21769/BioProtoc.4326. PMID: 35340300; PMCID: PMC8899558.
  21. Lake CM, Voss K, Bauman BM, Pohida K, Jiang T, Dveksler G, Snow AL. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1. Cell Death Dis. 2021 Apr 14;12(4):400. doi: 10.1038/s41419-021-03689-6. PMID: 33854046; PMCID: PMC8046753.
  22. Chen RH, Xiao ZW, Yan XQ, Han P, Liang FY, Wang JY, Yu ST, Zhang TZ, Chen SQ, Zhong Q, Huang XM. Tumor Cell-Secreted ISG15 Promotes Tumor Cell Migration and Immune Suppression by Inducing the Macrophage M2-Like Phenotype. Front Immunol. 2020 Dec 23;11:594775. doi: 10.3389/fimmu.2020.594775. PMID: 33424843; PMCID: PMC7785797.


Catalog Number : 05121-25 

ADDITIONAL INFORMATION

Clone:
OKT3
Format:
SAFIRE Purified
Applications:
FC, FA, IHC
Reactivity:
Human
Isotype:
Mouse IgG2a, kappa
Research Interest:Adaptive Immunity
Cell Type:NK and NKT Cells, T Cells, T Regulatory Cells, Th17 cells
Application:FC, FA, IHC
Clone:OKT3
Preparation:
The product should be stored undiluted at 4°C. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography. The endotoxin level is determined by LAL test to be less than 0.01 EU/µg of the protein.
Formulation:
Phosphate-buffered aqueous solution, ph7.2.
References:

Schlossman, S., L. Bloumsell, et al. eds (1995). Leucocyte Typing V: White Cell Differentiation Antigens. Oxford University Press. New York

Knapp W (1989) Leucocyte typing IV: white cell differentiation antigens. Oxford University Press, 1989.

Adair, J. R., Athwal, D. S., Bodmer, M. W., Bright, S. M., Collins, A. M., Pulito, V. L., … & Jolliffe, L. K. (1994). Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Human Antibodies, 5(1), 41-47.

BioGems SAFIRE 항체 : Anti-Human CD3 SAFIRE Purified ( OKT3 ) [ 05121-25 ]

본 정보는 "바이오젬스코리아"(으)로 문의 바랍니다.

목록

연구용제품 > 바이오젬스코리아

기업정보 바로가기 >

필코리아테크놀로지 AD